-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

Benzinga·08/06/2026 11:01:40
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.